Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2026-06-22 09:45:06 ET · period of report 2026-06-22 · accession 0001193125-26-276881 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-22 09:45 | 2026-06-22 | DFTX | Wiley Matthew T. | Chief Commercial Off | A - Grant | $0.00 | +62.5K | 177.5K | +54% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-06-22 | A | A | 62,500 | $0.00 | 177,500 | D | — | — | (F1) The common shares represent the first tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. |